A major new study has found that taking antidepressants during pregnancy does not increase the risk of autism spectrum disorder (ASD) or attention-deficit/hyperactivity disorder (ADHD) in children, offering reassurance to expectant mothers dealing with mental health conditions.
Researchers analysed health data from thousands of mothers and children and found no evidence that prenatal exposure to antidepressant medications directly caused neurodevelopmental disorders. Instead, experts say factors such as genetics, maternal mental health conditions, and family history may play a larger role in the development of autism or ADHD.
The findings challenge long-standing concerns surrounding the use of antidepressants during pregnancy, particularly selective serotonin reuptake inhibitors (SSRIs), which are commonly prescribed for depression and anxiety.
According to the researchers, untreated depression during pregnancy can itself pose serious risks, including poor prenatal care, premature birth, low birth weight, and emotional difficulties for both mother and baby. They stressed that women should not discontinue prescribed medications without consulting their doctors.
Mental health specialists welcomed the study, saying it could help reduce fear and stigma around seeking treatment during pregnancy. Experts noted that maintaining maternal mental well-being is essential for healthy fetal development and overall pregnancy outcomes.
Doctors recommend that treatment decisions during pregnancy should be individualized, balancing the benefits of antidepressant therapy against any potential risks. They also encourage regular consultation between pregnant women, psychiatrists, and obstetricians to ensure safe care.
The study adds to growing evidence suggesting that antidepressant use during pregnancy may be safer than previously believed, particularly when weighed against the dangers of untreated maternal depression.
